Pulse lineResearch With Heart Logo

ARIC Publications

Filters: Keyword is 1-Alkyl-2-acetylglycerophosphocholine Esterase  [Clear All Filters]
Journal Article
Pokharel Y, Mouhanna F, Nambi V, et al. "ApoB, small-dense LDL-C, Lp(a), LpPLA activity, and cognitive change." Neurology. 2019;92(22):e2580-e2593.
Folsom AR, Chambless LE, Ballantyne CM, et al. "An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study." Arch Intern Med. 2006;166(13):1368-73.
Garg PK, Bartz TM, Norby FL, et al. "Association of lipoprotein-associated phospholipase A and risk of incident atrial fibrillation: Findings from 3 cohorts." Am Heart J. 2018;197:62-69.
Peloso GM, Auer PL, Bis JC, et al. "Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks." Am J Hum Genet. 2014;94(2):223-32.
Agarwala A, Virani S, Couper DJ, et al. "Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study." Atherosclerosis. 2016;253:156-163.
Grallert H, Dupuis J, Bis JC, et al. "Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies." Eur Heart J. 2012;33(2):238-51.
Gregson JM, Freitag DF, Surendran P, et al. "Genetic invalidation of Lp-PLA as a therapeutic target: Large-scale study of five functional Lp-PLA-lowering alleles." Eur J Prev Cardiol. 2017;24(5):492-504.
Pokharel Y, Sun W, Polfus LM, et al. "Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study." Atherosclerosis. 2015;241(2):641-8.
Garg PK, Norby FL, Polfus LM, et al. "Lipoprotein-associated phospholipase A and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC)." Atherosclerosis. 2018;268:12-18.
Nambi V, Hoogeveen RC, Chambless L, et al. "Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study." Stroke. 2009;40(2):376-81.
Folsom AR, Lutsey PL, Roetker NS, Ballantyne CM, Hoogeveen RC, Rosamond WD. "Lipoprotein-associated phospholipase A2 and venous thromboembolism: a prospective study." Thromb Res. 2013;132(1):44-6.
Ballantyne CM, Hoogeveen RC, Bang H, et al. "Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study." Circulation. 2004;109(7):837-42.
Ballantyne CM, Hoogeveen RC, Bang H, et al. "Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study." Arch Intern Med. 2005;165(21):2479-84.